.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,076,362

« Back to Dashboard

Claims for Patent: 8,076,362

Title:Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof
Abstract: The invention relates to dosage forms and formulations comprising the novel crystal modification A of the compound I-(2,6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 .ANG., 5.14 .ANG., 4.84 .ANG., 4.55 .ANG., 4.34 .ANG., 4.07 .ANG., 3.51 .ANG., 3.48 .ANG., 3.25 .ANG., 3.19 .ANG., 3.15 .ANG., 3.07 .ANG., and 2.81 .ANG., determined by means of an X-ray powder pattern. Dosage forms of crystal modification A of the compound I-(2,6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide may be for oral or parenteral administration, in the form of a solid or liquid, and in a dosage range of 20 mg to less than 500 mg. Solid dosage forms comprise a tablet or capsule, and further comprise a pharmaceutically-acceptable carrier and film-coat.
Inventor(s): Portmann; Robert (Pratteln, CH), Hofmeier; Urs Christoph (St. Pantaleon, CH), Burkhard; Andreas (Basel, CH), Scherrer; Walter (Rheinfelden, CH), Szelagiewicz; Martin (Munchenstein, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:12/767,003
Patent Claims: 1. A solid dosage form for administration comprising an amount ranging from 20 mg to less than 500 mg of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and a solid pharmaceutically-acceptable carrier, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 .ANG., 5.14 .ANG., 4.84 .ANG., 4.55 .ANG., 4.34 .ANG., 4.07 .ANG., 3.51 .ANG., 3.48 .ANG., 3.25 .ANG., 3.19 .ANG., 3.15 .ANG., 3.07 .ANG., and 2.81 .ANG., determined by means of an X-ray powder pattern.

2. The dosage form of claim 1, wherein dosage is in the form of a tablet.

3. The dosage form of claim 1, wherein the amount ranges from 200 to 400 mg.

4. The dosage form of claim 1, further comprising one or more excipients.

5. The dosage form of claim 1, wherein the amount of crystal modification A ranges from approximately 100 mg to 400 mg.

6. The dosage form of claim 1, wherein dosage is in the form of a solid for oral administration.

7. The solid dosage form of claim 1, further comprising a film-coat.

8. The solid dosage form of claim 1, wherein the amount of crystal modification A comprises a dosage unit comprising 200 mg.

9. The solid dosage form of claim 1, wherein the amount of crystal modification A comprises a dosage unit comprising 400 mg.

10. A tablet for oral administration comprising a therapeutically-effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and microcrystalline cellulose wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 .ANG., 5.14 .ANG., 4.84 .ANG., 4.55 .ANG., 4.34 .ANG., 4.07 .ANG., 3.51 .ANG., 3.48 .ANG., 3.25 .ANG., 3.19 .ANG., 3.15 .ANG., 3.07 .ANG., and 2.81 .ANG., determined by means of an X-ray powder pattern.

11. The tablet of claim 10, having a dosage unit of crystal modification A ranging from 200 mg to 400 mg.

12. A tablet for oral administration comprising a therapeutically-effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, a pharmaceutically-acceptable carrier, and a film coat, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 .ANG., 5.14 .ANG., 4.84 .ANG., 4.55 .ANG., 4.34 .ANG., 4.07 .ANG., 3.51 .ANG., 3.48 .ANG., 3.25 .ANG., 3.19 .ANG., 3.15 .ANG., 3.07 .ANG. and 2.81 .ANG., determined by means of an X-ray powder pattern.

13. The tablet of claim 12, having a dosage unit of crystal modification A ranging from 20 mg to less than 500 mg.

14. The tablet of claim 12, having a dosage unit of crystal modification A ranging from 200 mg to 400 mg.

15. The tablet of claim 12, having a dosage unit of crystal modification A comprising 200 mg.

16. The tablet of claim 12, having a dosage unit of crystal modification A comprising 400 mg.

17. The tablet of claim 12, wherein the pharmaceutically-acceptable carrier comprises microcrystalline cellulose.

18. The tablet of claim 12, wherein the pharmaceutically-acceptable carrier comprises sodium carboxymethylcellulose.

19. The tablet of claim 12, wherein the film coat comprises hydroxypropylmethylcellulose.

20. The tablet of claim 12, wherein the pharmaceutically-acceptable carrier comprises microcrystalline cellulose and the film-coat comprises hydroxypropylmethylcellulose.

21. The tablet of claim 12, wherein the pharmaceutically-acceptable carrier comprises sodium carboxymethylcellulose and the film-coat comprises hydroxypropylmethylcellulose.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc